2017 Wses And Sicg Guidelines On Acute Calcolous

Assess patient risk and management recommendations based on the 2017 WSES/SICG guidelines

Introduction to Acute Calculous Cholecystitis

Acute calculous cholecystitis (ACC) represents one of the most common surgical emergencies worldwide, accounting for approximately 90-95% of all acute cholecystitis cases. The condition is characterized by inflammation of the gallbladder typically caused by obstruction of the cystic duct by gallstones, leading to bile stasis and secondary infection.

The 2017 World Society of Emergency Surgery (WSES) and Surgical Infection Society of China (SICG) guidelines provide evidence-based recommendations for the diagnosis and management of ACC, building upon the Tokyo Guidelines while incorporating regional specificities and updated evidence.

Pathophysiology and Risk Factors

The pathophysiology of ACC involves:

1. Biliary obstruction: Gallstones impact in the cystic duct or gallbladder neck
2. Chemical inflammation: Bile stasis leads to release of lysolecithin and other inflammatory mediators
3. Bacterial infection: Secondary infection occurs in 50-85% of cases, commonly with E. coli, Klebsiella, and Enterococcus
4. Ischemic injury: Increased intraluminal pressure compromises gallbladder perfusion

Major Risk Factors

• Female gender (2-3× higher risk than males)
• Age >40 years (peak incidence in 6th-7th decades)
• Obesity (BMI >30 kg/m²)
• Rapid weight loss or very low-calorie diets
• Family history of gallstones
• Diabetes mellitus (3× increased risk)
• Cirrhosis or chronic liver disease
• Prolonged fasting or total parenteral nutrition

Diagnostic Criteria and Classification

The 2017 WSES/SICG guidelines adopt a modified version of the Tokyo Guidelines diagnostic criteria, requiring:

Diagnostic Triad

A. Local Signs of Inflammation

• Murphy’s sign (sensitivity 65%, specificity 87%)
• Right upper quadrant pain/tenderness
• Palpable mass in RUQ (20-40% of cases)

B. Systemic Signs of Inflammation

• Fever (>38°C)
• Elevated CRP (>3 mg/dL)
• Leukocytosis (>10,000/μL)

C. Imaging Findings

• Gallbladder wall thickening (>3mm)
• Pericholecystic fluid
• Sonographic Murphy’s sign
• Gallstones with biliary sludge

Definitive diagnosis requires one item from A + one item from B + one item from C.

Severity Grading System

Grade	Criteria	Mortality Risk	Recommended Management
I (Mild)	Does not meet Grade II/III criteria	<1%	Early laparoscopic cholecystectomy (within 72h)
II (Moderate)	Any one of: – WBC >18,000/μL – Palpable tender RUQ mass – Duration >72h – Localized biliary peritonitis	1-5%	Early cholecystectomy if stable, otherwise percutaneous drainage
III (Severe)	Any one of: – Cardiovascular dysfunction (hypotension requiring dopamine ≥5 μg/kg/min) – Neurological dysfunction (GCS ≤14) – Respiratory dysfunction (PaO₂/FiO₂ ≤300) – Renal dysfunction (oliguria, creatinine >2.0 mg/dL) – Hepatic dysfunction (PT-INR >1.5) – Hematological dysfunction (platelets ≤100,000/μL)	10-30%	ICU management, percutaneous drainage, delayed cholecystectomy

Management Algorithms

Initial Resuscitation and Antibiotics

The guidelines emphasize:

• Fluid resuscitation: Crystalloid solutions to maintain urine output >0.5 mL/kg/h
• Pain control: NSAIDs preferred over opioids (ibuprofen 400mg IV shown to reduce inflammation)
• Antibiotic therapy: Should cover gram-negative bacilli and anaerobes
  • Mild-moderate: Ceftriaxone 2g IV + metronidazole 500mg IV
  • Severe: Piperacillin-tazobactam 4.5g IV q6h or meropenem 1g IV q8h
  • Duration: 4-7 days (longer for severe cases)

Timing of Cholecystectomy

The 2017 guidelines strongly recommend early laparoscopic cholecystectomy (within 72 hours of symptom onset) for:

• Grade I (mild) cases – Level 1A evidence
• Grade II (moderate) cases if hemodynamically stable – Level 1B evidence

Timing	Advantages	Disadvantages	Evidence Level
Early (<72h)	Reduced conversion to open (OR 0.35) Shorter hospital stay (mean 3.2 vs 5.8 days) Lower total costs ($8,300 vs $11,200) Lower readmission rates (8% vs 22%)	Higher technical difficulty Potential for increased bile duct injuries in inexperienced hands	1A
Delayed (6-12 weeks)	Easier dissection in inflamed tissue Lower conversion rates in some studies	20-30% readmission for recurrent symptoms Higher total healthcare costs Prolonged patient discomfort	2B

Alternative Approaches

For patients unfit for surgery:

• Percutaneous cholecystostomy: 85-95% technical success, 70-80% clinical success
  • Indicated for Grade III or failed medical management
  • Can serve as bridge to elective cholecystectomy
  • Complication rate: 10-15% (bleeding, bile leak, catheter dislodgment)
• Endoscopic gallbladder drainage: Emerging alternative with similar efficacy to percutaneous approach

Special Considerations

Elderly Patients

Patients >65 years present unique challenges:

• Atypical presentations in 30-40% (absence of fever, normal WBC)
• Higher complication rates (20% vs 8% in younger patients)
• Increased mortality (5% vs 1% for Grade II)
• Guidelines recommend:
  • Lower threshold for imaging (ultrasound + CT if needed)
  • Early surgical consultation even with mild symptoms
  • Consider frailty assessment (e.g., Clinical Frailty Scale)

Pregnant Patients

Management considerations:

• Incidence: 1-8 per 10,000 pregnancies
• Higher risk in 2nd/3rd trimesters due to progesterone-induced gallbladder hypomotility
• Diagnostic challenges:
  • Avoid radiation (MRCP preferred over ERCP)
  • Ultrasound has 95% sensitivity but may be limited by fetal position
• Management approach:
  • First trimester: Early cholecystectomy preferred (lowest fetal risk)
  • Second trimester: Conservative management with antibiotics, surgery if refractory
  • Third trimester: Conservative until postpartum if possible
  • Laparoscopic approach safe in all trimesters with proper precautions

Postoperative Management and Follow-up

The guidelines provide specific recommendations for postoperative care:

Immediate Postoperative Period

• Pain management:
  • Multimodal approach (acetaminophen + NSAIDs ± low-dose opioids)
  • Avoid NSAIDs in renal impairment or bleeding risk
• Diet advancement:
  • Clear liquids on POD #0 if no nausea
  • Regular diet as tolerated by POD #1-2
  • No evidence for routine fat restriction post-cholecystectomy
• Antibiotic duration:
  • Discontinue within 24h if no signs of infection
  • Continue 4-7 days if intraoperative purulent bile or gangrenous cholecystitis

Long-term Follow-up

Key recommendations:

• Routine follow-up at 2-4 weeks to assess:
  • Surgical site complications (1-5% incidence)
  • Persistent symptoms (10-15% report some GI changes)
  • Pathology results (incidental gallbladder cancer in 0.3-1.5%)
• Dietary counseling:
  • No need for long-term fat restriction
  • Gradual reintroduction of fatty foods as tolerated
  • Consider nutritional consult for malabsorption symptoms (<5% of patients)
• Bile duct injury surveillance:
  • Evaluate for “post-cholecystectomy syndrome” if persistent RUQ pain
  • MRCP if suspected bile duct stricture (incidence 0.2-0.5%)

Quality Indicators and Performance Metrics

The 2017 guidelines introduce quality metrics for institutional benchmarking:

Metric	Target	Rationale	Evidence Level
Time to antibiotics from diagnosis	<1 hour	Reduces progression to severe disease (OR 0.42)	1B
Time to cholecystectomy (Grade I/II)	<72 hours	Reduces conversion rates and hospital stay	1A
Laparoscopic approach rate	>90%	Lower morbidity vs open (12% vs 23%)	1A
Bile duct injury rate	<0.5%	Quality indicator for surgical technique	2B
30-day readmission rate	<10%	Marker of adequate initial treatment	2B
Mortality rate (Grade III)	<10%	Benchmark for ICU management	1B

Controversies and Future Directions

Antibiotic Duration

Ongoing debates include:

• Short-course (≤3 days) vs standard (5-7 days):
  • 2022 meta-analysis (JAMA Surg) showed no difference in outcomes
  • WSES 2023 update suggests 3-5 days may be sufficient for mild-moderate cases
• Oral vs IV antibiotics:
  • Oral bioavailability of fluoroquinolones/metronidazole approaches 100%
  • Potential for earlier discharge with oral step-down

Role of MRCP in Mild Cases

Emerging questions:

• Routine MRCP may identify 10-15% of patients with choledocholithiasis
• But adds $1,200-$1,800 per patient and delays definitive treatment
• 2021 WSES position: Reserve for:
  • Bilirubin >4 mg/dL
  • Dilated CBD (>6mm with stones, >8mm post-cholecystectomy)
  • Pancreatitis or cholangitis

Enhanced Recovery Protocols

Future directions include:

• Preoperative carbohydrates (12% maltodextrin 2-3h preop)
• Intraoperative dexamethasone (4-8mg) for PONV prophylaxis
• Transversus abdominis plane blocks for pain control
• Same-day discharge protocols for selected Grade I patients

Authoritative Resources

For further reading, consult these evidence-based sources:

• Infectious Diseases Society of America (IDSA) Guidelines – Comprehensive antibiotic recommendations
• American College of Surgeons (ACS) NSQIP Calculator – Surgical risk assessment tool
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) – Patient education resources